Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Moderate Versus Ultra Hypofractionation or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment

NCT04610372 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT04610372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04610372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Moderate Versus Ultra Hypofractionation or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Recruiting
Start date
July 12, 2021
Completion date
June 30, 2033
Enrollment
168 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic prostate cancer